A Randomized Open-Label Phase 3 Trial of Nivolumab and Ipilimumab versus Platinum-Doublet Chemotherapy in Early Stage NSCLC
Brief description of study
The main goal of this study is to assess the potential benefit of nivolumab (a PD-1 receptor blocker antibody) plus ipilimumab (a CTLA4 activator of immune cells) over platinum doublet chemotherapy as neoadjuvant therapy in Stage I-III resectable non-small cell lung cancer. This study will also evaluate the safety and tolerability of nivolumab and ipilimumab compared to platinum doublet chemotherapy, as well as assess how your view on life has been affected by your disease and the study drugs.
Clinical Study Identifier: s16-02049
ClinicalTrials.gov Identifier: NCTs16-02049
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.